0000000000403518

AUTHOR

Gerhard Scheuch

showing 3 related works from this author

The inhalation manager: a new computer-based device to assess inhalation technique and drug delivery to the patient.

2003

The rational choice of an inhalation device is a cornerstone in the effective management of asthma and COPD. In this publication, we describe the development of a new system, the Inhalation Manager, which, for the first time, offers the possibility to assess the entire inhalation maneuver of patients using original devices under everyday conditions. So far the Inhalation Manager allows the measurement of inspiratory maneuvers of patients through placebo inhalation devices of the most common breath-actuated CFC-free inhalers in the market for the three main glucocorticosteroids Budesonide [Turbohaler (TH), dry powder inhaler (DPI)], Beclomethasone dipropionate [Autohaler (AH), breath-actuate…

Pulmonary and Respiratory MedicineBudesonideAdultMaleInhalationAdolescentbusiness.industryInhalerNebulizers and VaporizersBeclometasone dipropionateMiddle AgedMetered-dose inhalerDry-powder inhalerFluticasone propionateDrug Delivery SystemsAnesthesiamedicineHumansPharmacology (medical)FemaleParticle SizebusinessFluticasonemedicine.drugJournal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine
researchProduct

Aerosolized GLP-1 for Treatment of Diabetes Mellitus and Irritable Bowel Syndrome

2014

Diabetes is a global burden and the prevalence of the disease, in particular diabetes mellitus type 2 is rapidly increasing worldwide. After introduction of insulin into clinical therapy about 90 years ago a major number of pharmaceuticals has been developed for treatment of diabetes mellitus type 2. One of these, the incretin glucagon-like peptide 1 (GLP-1), like insulin, needs subcutaneous administration causing inconvenience to patients. However, administration of GLP-1 plays also a role for treatment of irritable bowel syndrome (IBS). To improve patient convenience inhaled insulin (Exubera®) was developed and approved but failed market acceptance some years ago. Recently, another inhala…

Drugendocrine systemmedicine.medical_specialtyInhalationbusiness.industrymedia_common.quotation_subjectInsulinmedicine.medical_treatmentdigestive oral and skin physiologyIncretinDiseasemedicine.diseaseGlucagon-like peptide-1Diabetes mellitusInternal medicinemedicinebusinesshormones hormone substitutes and hormone antagonistsIrritable bowel syndromemedia_common
researchProduct

Mass Output and Particle Size Distribution of Glucocorticosteroids Emitted from Different Inhalation Devices Depending on Various Inspiratory Paramet…

2002

Efficient inhalation therapy depends on successful delivery of the drug to the lung. The efficacy of drug delivery is not only influenced by the characteristics of the inhalation device, but also by the patient's handling of the device and by the inspiratory maneuver achieved through the device. We analyzed the output characteristics of three different chlorofluorocarbon (CFC)-free breath-actuated inhalers for inhaled glucocorticosteroids (BUD Turbohaler, FP Diskus/Accuhaler and HFA-BDP Autohaler, respectively). Mass output and particle size distribution of drug aerosol delivered by the inhalers were determined depending on different inhalation parameters in vitro using an Andersen cascade …

AdultPulmonary and Respiratory MedicineAnti-Inflammatory AgentsPulmonary Disease Chronic Obstructivechemistry.chemical_compoundAdministration InhalationHumansPharmacology (medical)Particle SizeBudesonideChildPeak flow meterLungmeasurement_unitAerosolsChlorofluorocarbonInhalationNebulizers and VaporizersInhalerBeclomethasoneAsthmaAerosolAndrostadienesInhalationchemistryVolume (thermodynamics)Anesthesiameasurement_unit.measuring_instrumentRespiratory MechanicsFluticasoneParticleParticle sizeBiomedical engineeringJournal of Aerosol Medicine
researchProduct